Managing medications in clinically complex elders: "There's got to be a happy medium"

JAMA

Volumn 304, Issue 14, 2010, Pages 1592-1601

  Steinman, Michael A ^a,b   Hanlon, Joseph T ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIGOXIN; DIPHENHYDRAMINE; DOCUSATE SODIUM; ESSENTIAL FATTY ACID; ETODOLAC; GABAPENTIN; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; IRON; LACTULOSE; MEMANTINE; METOPROLOL; MULTIVITAMIN; NEUROLEPTIC AGENT; PARACETAMOL; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN D; WARFARIN;

ADVERSE OUTCOME; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN HEMORRHAGE; CAREGIVER; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; DEMENTIA; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MONITORING; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FALLING; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEALTH PRACTITIONER; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HEMORRHOID; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MALE; MEDICATION THERAPY MANAGEMENT; MINI MENTAL STATE EXAMINATION; PAIN; PHYSIOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SPEECH THERAPY; URINE RETENTION; CHRONIC DISEASE; CLINICAL PRACTICE; PATIENT COMPLIANCE; POLYPHARMACY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; MEDICATION THERAPY MANAGEMENT; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY;

EID: 77957916132     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1482     Document Type: Article

References (98)

1. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases. JAMA. 2005;294(6):716-724.
2. Slone Epidemiololgy Center at Boston University. Patterns of medication use in the United States, 2006. http://www.bu.edu/slone/SloneSurvey/AnnualRpt/ SloneSurveyWebReport2006.pdf. Accessed June 2, 2010.
3. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA. 2008;299(16):1922-1928. (Pubitemid 351574922)
4. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54(10):1516-1523. (Pubitemid 44564145)
5. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother. 2004;38(2):303-312.
6. Chrischilles E, Rubenstein L, Van Gilder R, Voelker M, Wright K, Wallace R. Risk factors for adverse drug events in older adults with mobility limitations in the community setting. J Am Geriatr Soc. 2007;55(1):29-34.
7. Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52(8):1349-1354.
8. Agostini JV, Han L, Tinetti ME. The relationship between number of medications and weight loss or impaired balance in older adults. J Am Geriatr Soc. 2004;52(10):1719-1723. (Pubitemid 41709927)
9. Magaziner J, Cadigan DA, Fedder DO, Hebel JR. Medication use and functional decline among community dwelling older women. J Aging Health. 1989;1:470-484 doi:10.1177/089826438900100404. (Pubitemid 20130393)
10. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107(2):169-173.
11. Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions. Ann Pharmacother. 2008;42(7):1017-1025.
12. Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci. 2006;61(5):511-515.
13. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107-1116.
14. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45(8):945-948.
15. Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drug reactions and related resource use. Ann Intern Med. 1992;117(8):634-640.
16. Steinman MA. Polypharmacy and the balance of medication benefits and risks. Am J Geriatr Pharmacother. 2007;5(4):314-316.
17. Gurwitz JH. Polypharmacy. Arch Intern Med. 2004;164(18):1957-1959.
18. Kaboli PJ, McClimon BJ, Hoth AB, Barnett MJ. Assessing the accuracy of computerized medication histories. Am J Manag Care. 2004;10(11 pt 2):872-877.
19. Bedell SE, Jabbour S, Goldberg R, et al. Discrepancies in the use of medications. Arch Intern Med. 2000;160(14):2129-2134.
20. Bayoumi I, Howard M, Holbrook AM, Schabort I. Interventions to improve medication reconciliation in primary care. Ann Pharmacother. 2009;43(10):1667-1675.
21. Weingart SN, Gandhi TK, Seger AC, et al. Patient-reported medication symptoms in primary care. Arch Intern Med. 2005;165(2):234-240.
22. Richard C, Lussier MT. Nature and frequency of exchanges on medications during primary care encounters. Patient Educ Couns. 2006;64(1-3):207-216.
23. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348(16):1556-1564.
24. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
25. Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539-545.
26. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74.
27. Wallsten SM, Sullivan RJ Jr, Hanlon JT, Blazer DG, Tyrey MJ, Westlund R. Medication taking behaviors in the high- and low-functioning elderly. Ann Pharmacother. 1995;29(4):359-364.
28. Cutler DM, Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med. 2010;362(17):1553-1555.
29. Feldstein AC, Smith DH, Perrin N, et al. Improved therapeutic monitoring with several interventions. Arch Intern Med. 2006;166(17):1848-1854.
30. Thompson CA. New health care laws will bring changes for pharmacists. Am J Health Syst Pharm. 2010;67(9):690-695.
31. Walter LC, Covinsky KE. Cancer screening in elderly patients. JAMA. 2001;285(21):2750-2756.
32. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med. 2006;166(6):605-609.
33. Reuben DB. Medical care for the final years of life. JAMA. 2009;302(24):2686-2694.
34. Brown AF, Mangione CM, Saliba D, Sarkisian CA; California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5 suppl guidelines):S265-S280.
35. Holmes HM, Sachs GA, Shega JW, Hougham GW, Cox Hayley D, Dale W. Integrating palliative medicine into the care of persons with advanced dementia. J Am Geriatr Soc. 2008;56(7):1306-1311.
36. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life. Drugs Aging. 2010;27(6):435-449.
37. Wenger NS, Solomon DH, Amin A, et al; ACOVE-3 Clinical Committee. Application of assessing care of vulnerable elders-3 quality indicators to patients with advanced dementia and poor prognosis. J Am Geriatr Soc. 2007;55(suppl 2):S457-S463. (Pubitemid 47512157)
38. Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428-437.
39. Cowper PA, Weinberger M, Hanlon JT, et al. The cost-effectiveness of a clinical pharmacist intervention among elderly outpatients. Pharmacotherapy. 1998;18(2):327-332.
40. Krska J, Cromarty JA, Arris F, et al. Pharmacist-led medication review in patients over 65. Age Ageing. 2001;30(3):205-211.
41. Lenaghan E, Holland R, Brooks A. Home-based medication review in a high risk elderly population in primary care - the POLYMED randomised controlled trial. Age Ageing. 2007;36(3):292-297.
42. Williams ME, Pulliam CC, Hunter R, et al. The short-term effect of interdisciplinary medication review on function and cost in ambulatory elderly people. J Am Geriatr Soc. 2004;52(1):93-98. (Pubitemid 38090396)
43. Schmader KE, Hanlon JT, Pieper CF, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med. 2004;116(6):394-401.
44. Weber V, White A, McIlvried R. An electronic medical record (EMR)-based intervention to reduce polypharmacy and falls in an ambulatory rural elderly population. J Gen Intern Med. 2008;23(4):399-404. (Pubitemid 351464872)
45. Pit SW, Byles JE, Cockburn J. Medication review. J Am Geriatr Soc. 2007;55(6):927-934.
46. Krska J, Gill D, Hansford D. Pharmacist-supported medication review training for general practitioners. Med Educ. 2006;40(12):1217-1225.
47. Drenth-van Maanen AC, van Marum RJ, Knol W, van der Linden CM, Jansen PA. Prescribing optimization method for improving prescribing in elderly patients receiving polypharmacy. Drugs Aging. 2009;26(8):687-701.
48. Drenth-van Maanen AC, van Marum RJ, Knol W, et al. Prescribing optimization method for improving prescribing in elderly patients receiving polypharmacy. Drugs Aging. 2009;26(8):687-701.
49. Higashi T, Shekelle PG, Solomon DH, et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med. 2004;140(9):714-720.
50. Hanlon JT, Schmader KE, Ruby CM, Weinberger M. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc. 2001;49(2):200-209. (Pubitemid 32207229)
51. Goulding MR. Inappropriate medication prescribing for elderly ambulatory care patients. Arch Intern Med. 2004;164(3):305-312.
52. Steinman MA, Rosenthal GE, Landefeld CS, Bertenthal D, Kaboli PJ. Agreement between drugs-to-avoid criteria and expert assessments of problematic prescribing. Arch Intern Med. 2009;169(14):1326-1332.
53. Doucette WR, McDonough RP, Klepser D, McCarthy R. Comprehensive medication therapy management. Clin Ther. 2005;27(7):1104-1111.
54. Boockvar KS, Liu S, Goldstein N, Nebeker J, Siu A, Fried T. Prescribing discrepancies likely to cause adverse drug events after patient transfer. Qual Saf Health Care. 2009;18(1):32-36.
55. Hajjar ER, Hanlon JT, Sloane RJ, et al. Unnecessary drug use in frail older people at hospital discharge. J Am Geriatr Soc. 2005;53(9):1518-1523. (Pubitemid 41602441)
56. Hajjar ER, Hanlon JT, Artz MB, et al. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother. 2003;1(2):82-89.
57. Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother. 2007;5(1):31-39.
58. Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189-193. (Pubitemid 44673747)
59. Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122-129.
60. Simon SR, Chan KA, Soumerai SB, et al. Potentially inappropriate medication use by elderly persons in US health maintenance organizations, 2000-2001. J Am Geriatr Soc. 2005;53(2):227-232.
61. Pugh MJ, Hanlon JT, Zeber JE, Bierman A, Cornell J, Berlowitz DR. Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure. J Manag Care Pharm. 2006;12(7):537-545.
62. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly. JAMA. 2001;286(22):2823-2829.
63. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults. Arch Intern Med. 2003;163(22):2716-2724.
64. Ryan C, O'Mahony D, Kennedy J, Weedle P, Byrne S. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol. 2009;68(6):936-947.
65. Bain KT, Holmes HM, Beers MH, Maio V, Handler SM, Pauker SG. Discontinuing medications. J Am Geriatr Soc. 2008;56(10):1946-1952.
66. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people. BMJ. 1997;315(7115):1096-1099.
67. Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older. Drugs Aging. 2008;25(12):1021-1031.
68. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63(2):214-219.
69. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? Int J Geriatr Psychiatry. 2003;18(11):988-993.
70. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Arch Neurol. 2003;60(6):843-848. (Pubitemid 36705972)
71. Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes. Ann Intern Med. 2009;151(12):854-860.
72. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
73. Mant J, Hobbs FD, Fletcher K, et al; BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA). Lancet. 2007;370(9586):493-503.
74. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952-1960.
75. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA. 2005;294(15):1934-1943.
76. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147(11):755-765.
77. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997;157(15):1681-1686. (Pubitemid 27327403)
78. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab. 2000;26(suppl 4):73-85. (Pubitemid 30618360)
79. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events. Diabetes Care. 2007;30(2):389-394.
80. Lipton HL, Bero LA, Bird JA, McPhee SJ. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing. Med Care. 1992;30(7):646-658.
81. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls. JAMA. 2004;291(16):1999-2006.
82. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. Arch Intern Med. 2009;169(6):551-561.
83. Scott IA, Guyatt GH. Cautionary tales in the interpretation of clinical studies involving older persons. Arch Intern Med. 2010;170(7):587-595.
84. Gerety MB, Cornell JE, Plichta DT, Eimer M. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc. 1993;41(12):1326-1332. (Pubitemid 23353943)
85. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy. Isr Med Assoc J. 2007;9(6):430-434.
86. Graves T, Hanlon JT, Schmader KE, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med. 1997;157(19):2205-2210. (Pubitemid 27451146)
87. Scuffham PA, Nikles J, Mitchell GK, et al. Using n-of-1 trials to improve patient management and save costs. J Gen Intern Med. 2010;25(9):906-913.
88. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions. Arch Intern Med. 2007;167(6):540-550.
89. Conn VS, Hafdahl AR, Cooper PS, Ruppar TM, Mehr DR, Russell CL. Interventions to improve medication adherence among older adults. Gerontologist. 2009;49(4):447-462.
90. Russell CL, Conn VS, Jantarakupt P. Older adult medication compliance. Am J Health Behav. 2006;30(6):636-650.
91. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296- 1310.
92. Hsu J, Fung V, Price M, et al. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA. 2008;299(16):1929-1936.
93. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296(15):1858-1866.
94. Raebel MA, Ross C, Xu S, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med. 2010;25(4):326-333.
95. Hurley JS, Roberts M, Solberg LI, et al. Laboratory safety monitoring of chronic medications in ambulatory care settings. J Gen Intern Med. 2005;20(4):331-333. (Pubitemid 40617601)
96. Raebel MA, McClure DL, Simon SR, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2007;16(1):55-64.
97. National Committee for Quality Assurance. HEDIS 2010 . http://www.ncqa.org/tabid/1044/Default.aspx. Accessed May 4, 2010.
98. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55(suppl 2):S373-S382.